- Home
- BOW vs ABUS Comparison
BOW vs ABUS Comparison
Compare BOW & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- ABUS
- Stock Information
- Founded
- BOW 2020
- ABUS N/A
- Country
- BOW United States
- ABUS United States
- Employees
- BOW N/A
- ABUS N/A
- Industry
- BOW Property-Casualty Insurers
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- ABUS Health Care
- Exchange
- BOW Nasdaq
- ABUS Nasdaq
- Market Cap
- BOW 880.2M
- ABUS 725.9M
- IPO Year
- BOW 2024
- ABUS N/A
- Fundamental
- Price
- BOW $33.51
- ABUS $3.64
- Analyst Decision
- BOW Hold
- ABUS Strong Buy
- Analyst Count
- BOW 5
- ABUS 4
- Target Price
- BOW $31.40
- ABUS $5.38
- AVG Volume (30 Days)
- BOW 350.3K
- ABUS 830.2K
- Earning Date
- BOW 11-05-2024
- ABUS 11-06-2024
- Dividend Yield
- BOW N/A
- ABUS N/A
- EPS Growth
- BOW 130.44
- ABUS N/A
- EPS
- BOW 1.08
- ABUS N/A
- Revenue
- BOW $389,135,000.00
- ABUS $6,742,000.00
- Revenue This Year
- BOW N/A
- ABUS N/A
- Revenue Next Year
- BOW $31.08
- ABUS N/A
- P/E Ratio
- BOW $31.03
- ABUS N/A
- Revenue Growth
- BOW 107.43
- ABUS N/A
- 52 Week Low
- BOW $22.14
- ABUS $1.77
- 52 Week High
- BOW $34.49
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- ABUS 36.59
- Support Level
- BOW N/A
- ABUS $3.61
- Resistance Level
- BOW N/A
- ABUS $3.81
- Average True Range (ATR)
- BOW 0.00
- ABUS 0.16
- MACD
- BOW 0.00
- ABUS -0.03
- Stochastic Oscillator
- BOW 0.00
- ABUS 34.87
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc is engaged in providing specialty P&C products. It is a specialty insurance group that generates revenues by underwriting and offering a variety of specialty insurance products to domestic markets through three distinct underwriting divisions: Casualty, Professional Liability and Healthcare. Casualty specialize in GL coverage for risks in the construction, distribution, heavy manufacturing, real estate and hospitality segments and also consider underwriting risks in a broader range of industries. Key revenue is generated from Casualty segment.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.